Algernon Health, Inc. (AGN.CX)
0.08
0.00 (0.00%)
CAD |
CNSX |
Dec 08, 15:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.740M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 6.67% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.574 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.52% |
Profile
| Algernon Health, Inc. is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them into new human trials, developing new formulations and seeking new regulatory approvals in global markets. It specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. The company was founded on January 22, 2015 and is headquartered in Vancouver, Canada. |
| URL | http://www.algernonpharmaceuticals.com |
| Investor Relations URL | N/A |
| HQ State/Province | British Columbia |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Algernon Health, Inc. is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them into new human trials, developing new formulations and seeking new regulatory approvals in global markets. It specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. The company was founded on January 22, 2015 and is headquartered in Vancouver, Canada. |
| URL | http://www.algernonpharmaceuticals.com |
| Investor Relations URL | N/A |
| HQ State/Province | British Columbia |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |